Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States

By sjmartinez • January 7, 2023

Nicholas SB, Alicic RZ, Shen J. Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States. Kidney Med. 2022 Dec 15;5(1):100590. doi: 10.1016/j.xkme.2022.100590. PMID: 36605084; PMCID: PMC9807823.

Tags: Harbor UCLA, Nephrology, Publications

Facilitators and challenges in the implementation of the Care Ecosystem at six clinical sites in the United States: A qualitative study

Sideman AB, Merrilees J, Dulaney S, Allawala M, Barclay M, Rosenbloom M, Hanson LR, Ward KT, Hess M, Olney NT, Lum HD, Sawyer RJ, Possin[...]

Berger disease redux

Glassock RJ. Berger disease redux. Kidney Int. 2025 Dec;108(6):999-1001. doi: 10.1016/j.kint.2025.09.021. PMID: 41271316.

Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

Bolla E, Semb AG, Petri M, Sfikakis PP, Artim-Esen B, Hernandez-Molina G, Hachulla E, Direskeneli H, Karpouzas GA, Zucchi D, Goyal M, Costedoat-Chalumeau N, Tincani[...]